Two‐year efficacy of SNK01 plus pembrolizumab for non‐small cell lung cancer: Expanded observations from a phase I/IIa randomized controlled trial

por Park, Hyung Jun, Kim, Yong Man, Jung, Jae Seob, Ji, Wonjun, Lee, Jae Cheol, Choi, Chang‐Min
Publicado 2022

A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non–Small Cell Lung Cancer

por Kim, Eo Jin, Cho, Yong-Hee, Kim, Dong Ha, Ko, Dae-Hyun, Do, Eun-Ju, Kim, Sang-Yeob, Kim, Yong Man, Jung, Jae Seob, Kang, Yoonmi, Ji, Wonjun, Choi, Myeong Geun, Lee, Jae Cheol, Rho, Jin Kyung, Choi, Chang-Min
Publicado 2022